Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is in advanced discussions with fellow Japanese firm Yaskawa Electric Corporation (OTCMKTS: YASKY) to explore a potential collaboration aimed at developing a cell therapy platform. This strategic partnership would integrate robotics technologies to expedite research and development (R&D) timelines and speed up the commercialization process, thereby empowering start-ups and academic institutions to autonomously roll out these innovative treatments.
The proposed collaboration builds on a previous partnership between the two companies, which resulted in Yaskawa developing a cell therapy manufacturing robot. Astellas subsequently implemented this robot in its operations in 2017, showcasing the potential synergy of their combined expertise.- Flcube.com
